期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

纤溶酶原激活物抑制物1与肾脏疾病 被引量：1

原文传递
导出
摘要 肾脏疾病患者肾脏局部纤溶酶原激活物抑制物1(PAI-1)表达增加,抑制了肾小球与肾小管间质细胞外基质(ECM)的降解,导致ECM进行性堆积,肾小球基底膜增厚,肾小球硬化。血管紧张素Ⅱ及脂肪酸在转录水平上可上调PAI-1基因表达,高糖、糖基化终末产物增加PAI-1的含量和活性,转化生长因子-β和结缔组织生长因子反义寡核苷酸能诱导PAI-1的产生,从而导致肾小球硬化的发生。而大黄酸抑制PAI-1的产生。PAI-1抑制剂的应用将对防治肾脏疾病起一定的作用。
作者 宋彩霞 何正宏 白云凯
机构地区 昆明医学院附一院肾内科
出处 《国际泌尿系统杂志》 2006年第1期88-92,共5页 International Journal of Urology and Nephrology
关键词 肾疾病 纤溶酶原激活物抑制物1
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献3

二级参考文献25

  • 1Allison A. Eddy.Molecular basis of renal fibrosis[J].Pediatric Nephrology (-).2000(3-4)
  • 2BeckerGJ,HewitsonTD etal.Theroleoftubulointerstitialinjuryinchronicrenalfailure[].Current Opinion in Nephrology and Hypertension.2000
  • 3HeidlandA,SebekovaK,PaczekL etal.Renalfibrosis:roleofimpairedproteolysisandpotentialtherapeuticstrategies[].KidneyIntSuppl.1997
  • 4YokoiH,SugawaraA,MukoyamaM etal.Roleofconnectivetissuegrowthfactorinprofibroticactionoftransforminggrowthfactorβ:apotentialtargetforpreventingrenalfibrosis[].AmJKidneyDis.2002
  • 5IgarashiA,OkochiH,GrotendorstGR.Regulationofconnectivetissuegrowthfactorgeneexpressioninhumanskinfibroblastsandduringwoundrepair[].MolBiolCell.1993
  • 6FrazierK,WilliamsS,GrotendorstGR etal.Stimulationoffibroblastcellgrowth matrixproduction andgranulationtissueformationbyconnectivetissuegrowthfactor[].JInvestDermatol.1996
  • 7HanDC,HoffmanBB,HongSW etal.TherapywithantisenseTGF beta1oligodeoxynucleotidesreduceskidneyweightandmatrixmRNAindiabeticmice[].AmJPhysiolRenalPhysiol.2000
  • 8InoueT,OkadaH,KobayashiT etal.TGF beta1andHGFcoordinatelyfacilitatecollagenturnoverinsubepithelialmesenchyme[].Biochemical and Biophysical Research Communications.2002
  • 9DuncanMR,FrazierKS,AbramsonS etal.Connectivetissuegrowthfactormediatestransforminggrowthfactorβ inducedcollagensynthesis:down regulationbycAMP[].The FASEBJ Journal.1999
  • 10Roberts AB,McCune BK,Sporn MB.TGF-β: Regulation of extracellular matrix[].Kidney International.1992

共引文献70

同被引文献8

  • 1Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome-activated receptor-gamma in mesangial cells. Hypertention, 2001,37(2):722-727.
  • 2Gabat S,Keller C,Conni C,et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease.Thromb Res, 2001,71 (6):423-431.
  • 3Seigneur M,Dufourcq P,Conni C,et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease.Thromb Res,2001,71 (6):423-431.
  • 4Uehara S,Gotoh K,Handa H. Separtion and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. Thromb Res,2001,104(5):322-325.
  • 5Vaughan DE. Angiotensin,fibrinolysis,and vascular homeostasis. Am J Cardiol,2001,87(8A):18C-24C.
  • 6Kenichi M, Masanobu M, Takehiko K, et al. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plas-minogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. Lab Clin Med, 2004,144(2):69-77.
  • 7Basile DP. Is angiotensin Ⅱ s role in fiborsis as easy as PAI-1. Kidney Int, 2000,58:460-461.
  • 8王凌云,柳洁.氧化应激和糖尿病肾病的研究进展[J].山西医药杂志（下半月）,2007,36(9):734-736. 被引量：5

引证文献1

国际泌尿系统杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部